BRPI0407283A - Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade - Google Patents

Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade

Info

Publication number
BRPI0407283A
BRPI0407283A BR0407283-9A BRPI0407283A BRPI0407283A BR PI0407283 A BRPI0407283 A BR PI0407283A BR PI0407283 A BRPI0407283 A BR PI0407283A BR PI0407283 A BRPI0407283 A BR PI0407283A
Authority
BR
Brazil
Prior art keywords
compound
agents
obesity
pharmaceutical composition
diabetes mellitus
Prior art date
Application number
BR0407283-9A
Other languages
English (en)
Inventor
Morihiro Mitsuya
Makoto Bamba
Fumiko Sakai
Hitomi Watanabe
Yasuhiro Sasaki
Teruyuki Nishimura
Jun-Ichi Eiki
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of BRPI0407283A publication Critical patent/BRPI0407283A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, E, AGENTE ATIVADOR DE GLUCOQUINASE, AGENTES TERAPêUTICOS E/OU AGENTES PREVENTIVOS PARA DIABETES MELITO E OBESIDADE". A presente invenção refere-se a um composto que apresenta um efeito ativador de glucoquinase e que é útil como um agente terapêutico para diabetes melito, sendo que é representado pela fórmula (I): ¢em que X¬ 1¬ representa a átomo de nitrogênio, átomo de enxofre, átomo de oxigênio ou análogos; R¬ 1¬ representa um grupo arila com de 6 a 10 membros, grupo heteroarila com de 5 a 7 membros ou análogos; D representa um átomo de oxigênio ou átomo de enxofre; R¬ 2¬ e R¬ 3¬ são iguais ou diferentes, cada um representando um átomo de hidrogênio, grupo alquila inferior ou análogo; uma fórmula (II) representa um grupo heteroarila com de 5 a 7 membros opcionalmente substituído ou análogo; uma fórmula (III) representa um grupo heteroarila monocíclico ou bicíclico! ou um sal farmaceuticamente aceitável do mesmo.
BR0407283-9A 2003-02-13 2004-02-13 Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade BRPI0407283A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2003034987 2003-02-13
JP2003342860 2003-10-01
JP2004014799 2004-01-22
PCT/JP2004/001568 WO2004081001A1 (ja) 2003-02-13 2004-02-13 新規２－ピリジンカルボキサミド誘導体

Publications (1)

Publication Number Publication Date
BRPI0407283A true BRPI0407283A (pt) 2006-01-31

Family

ID=32995582

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0407283-9A BRPI0407283A (pt) 2003-02-13 2004-02-13 Composto, composição farmacêutica, e, agente ativador de glucoquinase, agentes terapêuticos e/ou agentes preventivos para diabetes melito e obesidade

Country Status (20)

Country Link
US (3) US7629362B2 (pt)
EP (1) EP1598349B1 (pt)
JP (1) JP4400563B2 (pt)
KR (1) KR20050101208A (pt)
AR (1) AR045414A1 (pt)
AT (1) ATE517887T1 (pt)
AU (2) AU2004220234C1 (pt)
BR (1) BRPI0407283A (pt)
CA (1) CA2515841C (pt)
EC (1) ECSP056016A (pt)
IL (1) IL169905A0 (pt)
MA (1) MA27626A1 (pt)
MX (1) MXPA05008619A (pt)
NO (1) NO20054224L (pt)
NZ (1) NZ540791A (pt)
PE (1) PE20050194A1 (pt)
TW (1) TWI336329B (pt)
UA (1) UA82867C2 (pt)
WO (1) WO2004081001A1 (pt)
ZA (1) ZA200504852B (pt)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
MXPA05003559A (es) 2002-10-03 2005-06-03 Novartis Ag (tiazol-2-il)-amida o sulfonamida substituida como activadores de glicocinasa utiles en el tratamiento de diabetes de tipo 2.
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
US7629362B2 (en) 2003-02-13 2009-12-08 Banyu Pharmaceutical Co., Ltd. 2-pyridine carboxamide derivatives
AU2004220548A1 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
US7728025B2 (en) * 2003-12-29 2010-06-01 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted benzimidazole derivative
US8710045B2 (en) 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
JP2007524682A (ja) * 2004-02-12 2007-08-30 メルク　エンド　カムパニー　インコーポレーテッド 代謝調節型グルタミン酸受容体−５の調節物質としてのビピリジルアミド
KR20070006816A (ko) 2004-04-02 2007-01-11 노파르티스 아게 티아졸로피리딘 유도체, 이를 함유하는 제약 조성물 및글루코키나제 매개형 증상의 치료 방법
AU2005229416B2 (en) 2004-04-02 2009-03-26 Novartis Ag Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
JPWO2006038741A1 (ja) 2004-10-08 2008-05-15 萬有製薬株式会社 チオエーテル化合物の製造方法
AU2005301608B2 (en) 2004-11-02 2012-09-13 Msd K.K. Aryloxy-substituted benzimidazole derivatives
AU2006217677A1 (en) * 2005-02-25 2006-08-31 Takeda Pharmaceutical Company Limited Pyridyl acetic acid compounds
US7414060B2 (en) 2005-03-04 2008-08-19 Hoffmann-La Roche Inc. Pyridine-2-carboxyamide derivatives
NZ564608A (en) 2005-07-09 2009-09-25 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
WO2007019210A1 (en) 2005-08-05 2007-02-15 Bristol-Myers Squibb Company Preparation of 2-amino-thiazole-5-carboxylic-acid derivatives
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CA2624102A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
CA2623958C (en) 2005-09-30 2013-05-28 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted indole derivative
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
DE602006018496D1 (de) 2005-10-05 2011-01-05 Hoffmann La Roche Naphthyridin-derivate
ATE521608T1 (de) * 2005-11-01 2011-09-15 Array Biopharma Inc Glucokinaseaktivatoren
US8034822B2 (en) 2006-03-08 2011-10-11 Takeda San Diego, Inc. Glucokinase activators
EP2543667B1 (en) * 2006-03-24 2015-01-28 Array Biopharma, Inc. A method of preparing 2-aminopyridine analogs as glucokinase activators
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
MX2009000688A (es) 2006-07-24 2009-01-30 Hoffmann La Roche Pirazoles como activadores de glucocinasa.
AR063028A1 (es) * 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
ATE542818T1 (de) * 2006-10-11 2012-02-15 Amgen Inc Imidazo- und triazolopyridinverbindungen und verfahren zu deren anwendung
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
US8314247B2 (en) * 2007-01-10 2012-11-20 Mitsubishi Tanabe Pharma Corporation Hydrazone derivative
US8431713B2 (en) 2007-01-24 2013-04-30 Array Biopharma, Inc. 2-aminopyridine derivatives as glucokinase activators
WO2008116107A2 (en) 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
CA2681695A1 (en) * 2007-03-23 2008-10-02 Array Biopharma Inc. 2-aminopyridine analogs as glucokinase activators
JP2010138073A (ja) * 2007-03-30 2010-06-24 Taisho Pharmaceutical Co Ltd ピコリン酸アミド化合物
WO2008156174A1 (ja) 2007-06-21 2008-12-24 Taisho Pharmaceutical Co., Ltd. ピラジンアミド化合物
EP2020232A1 (en) * 2007-08-03 2009-02-04 Zeltia, S.A. N-(1-thiazolyl)-amide derivatives for the treatment of obesity, diabetes and cardiovascular diseases
UA101166C2 (ru) 2007-09-21 2013-03-11 Аррей Биофарма Инк. Производные пиридин-2-иламино-1,2,4-тиадиазола как активаторы глюкокиназы для лечения сахарного диабета
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
CA2703996A1 (en) 2007-11-06 2009-05-14 Astrazeneca Ab Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
AU2008321959B2 (en) 2007-11-12 2014-02-13 Msd K.K. Heteroaryloxy quinazoline derivative
CA2707403A1 (en) * 2007-12-25 2009-07-02 Banyu Pharmaceutical Co., Ltd. N-pyrazole-2-pyridinecarboxamide derivative
WO2009083553A1 (en) * 2007-12-31 2009-07-09 Rheoscience A/S Azine compounds as glucokinase activators
KR20100117137A (ko) * 2008-02-27 2010-11-02 메르크 파텐트 게엠베하 당뇨병 치료를 위한 카르복사마이드-헤테로아릴유도체
JP5498025B2 (ja) * 2008-03-13 2014-05-21 公益財団法人相模中央化学研究所 新規なチアゾール誘導体固定化マトリックス、及びその製造方法
JP5455380B2 (ja) * 2008-03-12 2014-03-26 公益財団法人相模中央化学研究所 新規なチアゾール誘導体、及びその製造方法
WO2009113637A1 (ja) * 2008-03-12 2009-09-17 東ソー株式会社 新規なチアゾール誘導体、チアゾール誘導体固定化マトリックス、及びそれらの製造方法
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
JP2012500181A (ja) 2008-08-15 2012-01-05 Ｍｓｄ株式会社 アセチルピロリジニルインドール誘導体
EP2328892B1 (en) * 2008-08-29 2013-01-16 Msd K.K. Oxotetrahydrofuran-2-yl-benzimidazole derivative
PE20110303A1 (es) 2008-09-11 2011-05-21 Pfizer Derivados de heteroaril acetamidas como activadores de glucoquinasa
US8759539B2 (en) 2008-11-17 2014-06-24 Merck Sharp & Dohme Corp. Substituted bicyclic amines for the treatment of diabetes
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
ES2427279T3 (es) 2009-03-11 2013-10-29 Pfizer Inc. Derivados de benzofuranilo usados como inhibidores de glucocinasa
US20110021570A1 (en) * 2009-07-23 2011-01-27 Nancy-Ellen Haynes Pyridone glucokinase activators
US20120220567A1 (en) 2009-07-23 2012-08-30 Shipps Jr Gerald W Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
NZ598262A (en) 2009-08-17 2014-05-30 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
KR101737151B1 (ko) * 2009-12-04 2017-05-17 닛산 가가쿠 고교 가부시키 가이샤 2-피리돈 화합물
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
US8178689B2 (en) 2010-06-17 2012-05-15 Hoffman-La Roche Inc. Tricyclic compounds
US20150057220A1 (en) 2012-04-16 2015-02-26 Kaneq Pharma Inc. Fused aromatic phosphonate derivatives as precursors to ptp-1b inhibitors
US9527838B2 (en) 2012-12-17 2016-12-27 Merck Sharp & Dohme Corp. 2-pyridinecarboxamide derivatives, compositions containing such compounds, and methods of treatment
EA201692155A1 (ru) 2014-05-13 2017-04-28 Мемориал Слоун-Кеттеринг Кэнсэ Сентр МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
WO2022146755A1 (en) * 2020-12-29 2022-07-07 Merck Sharp & Dohme Corp. Amido-substituted pyridyl compounds and methods of use thereof for the treatment of herpesviruses
IL280384B (en) * 2021-01-25 2022-09-01 Ag Plenus Ltd Herbicidal compounds and methods of use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
JPS56115784A (en) 1980-02-15 1981-09-11 Tanabe Seiyaku Co Ltd Novel pyridinecarboxamide derivative and its preparation
JPS5795984A (en) 1980-12-05 1982-06-15 Tanabe Seiyaku Co Ltd Pyridinecarboxamide derivative and its preparation
JPS58121215A (ja) 1982-01-14 1983-07-19 Tanabe Seiyaku Co Ltd 抗アレルギ−剤
CH680582A5 (pt) 1991-04-23 1992-09-30 Supermatic Kunststoff Ag
GB2277930A (en) 1993-05-11 1994-11-16 Shell Int Research Herbicidal picolinamide derivatives
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
GB9725298D0 (en) 1997-11-28 1998-01-28 Zeneca Ltd Insecticidal thiazole derivatives
JP2002047278A (ja) 2000-08-02 2002-02-12 Fuji Photo Film Co Ltd チオエーテル化合物の製造方法
JP4723059B2 (ja) 2000-08-03 2011-07-13 帝人化成株式会社 難燃性熱可塑性樹脂組成物
SE0102300D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
SE519859C2 (sv) 2001-08-17 2003-04-15 Novacast Ab Anordning för behandling av järnlegeringar i ett kärl
AU2002952839A0 (en) 2002-11-21 2002-12-05 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
US7629362B2 (en) 2003-02-13 2009-12-08 Banyu Pharmaceutical Co., Ltd. 2-pyridine carboxamide derivatives
MXPA05009059A (es) * 2003-02-26 2005-10-19 Banyu Pharma Co Ltd Derivados de heteroarilcarbamoilbenceno.
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
CA2554686A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Compounds
BRPI0507746A (pt) 2004-02-18 2007-07-10 Astrazeneca Ab composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
JPWO2006038741A1 (ja) 2004-10-08 2008-05-15 萬有製薬株式会社 チオエーテル化合物の製造方法
AR063028A1 (es) * 2006-10-06 2008-12-23 Banyu Pharma Co Ltd Derivados heterociclicos de piridin-2-carboxamida activadores de glucoquinasas, utiles para el tratamiento de diabetes y obesidad y composiciones farmaceuticas que los contienen.
AR068540A1 (es) 2007-09-28 2009-11-18 Merck & Co Inc Metodos de produccion de un derivado de pirazol-3-il-benzamida.

Also Published As

Publication number Publication date
AU2010200004B2 (en) 2012-07-19
EP1598349A1 (en) 2005-11-23
IL169905A0 (en) 2007-07-04
US8344003B2 (en) 2013-01-01
ECSP056016A (es) 2006-01-27
US20130085156A1 (en) 2013-04-04
KR20050101208A (ko) 2005-10-20
WO2004081001A1 (ja) 2004-09-23
JPWO2004081001A1 (ja) 2006-06-08
MXPA05008619A (es) 2005-11-04
ATE517887T1 (de) 2011-08-15
NO20054224D0 (no) 2005-09-12
ZA200504852B (en) 2006-05-31
EP1598349B1 (en) 2011-07-27
NO20054224L (no) 2005-11-10
UA82867C2 (en) 2008-05-26
HK1088602A1 (zh) 2006-11-10
US20100041660A1 (en) 2010-02-18
CA2515841C (en) 2010-06-01
TW200510381A (en) 2005-03-16
AU2004220234B2 (en) 2009-11-26
AU2004220234C1 (en) 2013-01-17
EP1598349A4 (en) 2008-12-31
AR045414A1 (es) 2005-10-26
PE20050194A1 (es) 2005-04-23
AU2004220234A1 (en) 2004-09-23
MA27626A1 (fr) 2005-11-01
US20060258701A1 (en) 2006-11-16
NZ540791A (en) 2009-09-25
JP4400563B2 (ja) 2010-01-20
AU2010200004A1 (en) 2010-01-28
US7629362B2 (en) 2009-12-08
US8765789B2 (en) 2014-07-01
CA2515841A1 (en) 2004-09-23
TWI336329B (en) 2011-01-21

Similar Documents

Publication Publication Date Title
BRPI0407810A (pt) composto, composição farmacêutica, ativador da glicocinase, e, medicamento
ECSP056016A (es) Nuevos derivados de 2-piridinacarboxamida
BR112012026948A2 (pt) composto, composição farmacêutica, e, métodos para melhorar o metabolismo ósseo, para previnir ou tratar uma doença associada com metabolismo ósseo e para previnir ou tratar osteoporose.
BRPI0313880B8 (pt) composto
BRPI0415960A (pt) composto ou um sal do mesmo, pró-droga de um composto, agente farmacêutico, inibidor de peptidase, composto ou um sal do mesmo, pró-droga de um composto, agente farmacêutico, inibidor de peptidase, uso de um composto,e, método para produzir um composto
BRPI0818193B8 (pt) composto, composição farmacêutica, e, uso de um composto
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
BR0213877A (pt) Compostos orgânicos
BRPI0708038B8 (pt) derivado de cumarina, composição farmacêutica e agente terapêutico para um distúrbio proliferativo celular
BRPI0409241A (pt) compostos bicìclicos como antagonistas do receptor de nr2b, composições farmacêuticas compreendendo os mesmos e seu uso
CY1108794T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
BRPI0409136A (pt) composto heteroaromático pentacìclico e uso medicinal do mesmo
BR0308784A (pt) Miméticos de glucocorticóides, métodos para fabricar os mesmos, composições farmacêuticas e usos dos mesmos
BRPI0417687A (pt) derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade
BRPI0517232A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, ativador da glicocinase, e, agentes terapêuticos e/ou profiláticos para diabetes e para obesidade
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
ATE450514T1 (de) Piperazinylalkylpyrazol-derivate zur verwendung als selektive calciumkanalblocker des t-typs und verfahren zu ihrer herstellung
BRPI0406721A (pt) Compostos condensados de furano
BR0310032A (pt) Derivados de benzoxazina como moduladores de 5-ht6 e usos dos mesmos
BR0309558A (pt) Derivados de quinazolina e medicamentos
BRPI0615248A2 (pt) derivado tendo atividade agonista de ppar
BRPI0406500A (pt) processo farmacêutico e compostos preparados pelo mesmo
ES2340502T3 (es) Compuestos de 1,4,8-triazaespiro(4,5)decan-2-ona sustituidos para el tratamiento de la obesidad.
BR0308419A (pt) Derivados de azetidina como antagonistas do receptor ccr-3

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]